Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02519413 · ClinicalTrials.gov registry record
Tecfidera Lymphocyte Chart Review
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 483
- Enrollment target
NCT02519413: Completed study, sponsored by Biogen.
NCT02519413 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 483 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02519413 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 483 participants
- Enrollment target
Study Summary
The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months. The secondary objective is to investigate changes in lymphocyte subtypes other than CD4+ and CD8+ T cells.
Interventions
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 483 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-02 |
What the finished NCT02519413 record still lists
NCT02519413 is an observational study that tracks outcomes without assigning an intervention. The registered 483 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which dimethyl fumarate is the first listed.
NCT02519413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02519413 about?
NCT02519413 is a clinical study titled "Tecfidera Lymphocyte Chart Review". The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months. The secondary objective is to investigate changes in lymphocyte subtypes other...
What is the current status of trial NCT02519413?
This trial is currently completed. The enrollment target is 483 participants. The study started on 2015-07. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02519413?
The interventions under investigation include: dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT02519413?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02871726 · 483 participants · NA
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
- NCT04449458 · 482 participants · NA
The Positively Quit Trial for Smoking Cessation
- NCT07079631 · 482 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia